Deutsche Bank
PSTX

Deutsche Bank’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Deutsche Bank’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-47,985
Closed -$461K – 3681
2024
Q4 		$461K Buy
47,985
+16,117
+51% +$84.1K ﹤0.01% 2651
2024
Q3 		$91.1K Buy
31,868
+7,593
+31% +$23.5K ﹤0.01% 3241
2024
Q2 		$70.9K Sell
24,275
-5,376
-18% -$14.7K ﹤0.01% 3240
2024
Q1 		$94.6K Buy
+29,651
New +$98.9K ﹤0.01% 3194
2023
Q4 		– Sell
-35,880
Closed -$85.4K – 3731
2023
Q3 		$85.4K Buy
+35,880
New +$75.2K ﹤0.01% 3229
2022
Q2 		– Sell
-15,619
Closed -$70K – 4367
2022
Q1 		$70K Sell
15,619
-1,858
-11% -$8.38K ﹤0.01% 3720
2021
Q4 		$119K Buy
17,477
+934
+6% +$6.36K ﹤0.01% 3631
2021
Q3 		$121K Sell
16,543
-532
-3% -$4.57K ﹤0.01% 3822
2021
Q2 		$171K Sell
17,075
-4,900
-22% -$43.9K ﹤0.01% 3872
2021
Q1 		$210K Buy
21,975
+11,347
+107% +$111K ﹤0.01% 3610
2020
Q4 		$117K Buy
10,628
+3,896
+58% +$41.1K ﹤0.01% 3764
2020
Q3 		$60K Buy
+6,732
New +$76.6K ﹤0.01% 3792

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Deutsche Bank's PSTX Position: Q1 2025 in Review

Deutsche Bank sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 47,985 shares — an estimated $461K sold.

Deutsche Bank first reported a position in PSTX in Q3 2020 and held it in 12 quarters. The position peaked at $461K in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • Deutsche Bank reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Deutsche Bank sold 47,985 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $461K.
  • Deutsche Bank first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 12 quarters.
  • Deutsche Bank's Poseida Therapeutics, Inc. Common Stock position peaked at $461K in Q4 2024.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Deutsche Bank's 13F filing for Q1 2025, filed 9 May 2025.